Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
107M
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
76.1M
-
Shares change
-
-2.11M
-
Total reported value, excl. options
-
$1.51B
-
Value change
-
-$36.1M
-
Put/Call ratio
-
1
-
Number of buys
-
76
-
Number of sells
-
-70
-
Price
-
$19.87
Significant Holders of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) as of Q2 2023
183 filings reported holding RCKT - ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share as of Q2 2023.
ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 76.1M shares
of 107M outstanding shares and own 70.95% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (17.7M shares), WELLINGTON MANAGEMENT GROUP LLP (5.14M shares), BlackRock Inc. (5.14M shares), VANGUARD GROUP INC (4.6M shares), MAVERICK CAPITAL LTD (4.38M shares), WESTFIELD CAPITAL MANAGEMENT CO LP (3.66M shares), STATE STREET CORP (3.18M shares), CITADEL ADVISORS LLC (2.59M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.12M shares), and Boxer Capital, LLC (1.47M shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.